Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


Our top-notch dedicated system is used to design specialised libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P98179

UPID:
RBM3_HUMAN

ALTERNATIVE NAMES:
RNA-binding motif protein 3; RNPL

ALTERNATIVE UPACC:
P98179

BACKGROUND:
The RNA-binding protein 3, also known as RNA-binding motif protein 3 or RNPL, is integral to the cellular response to temperature changes, facilitating enhanced protein synthesis at both normal and slightly reduced temperatures. This is achieved through a decrease in microRNA abundance and increased phosphorylation of key translation initiation factors, promoting active polysome formation. Such capabilities highlight the protein's adaptability and importance in maintaining cellular function under stress.

THERAPEUTIC SIGNIFICANCE:
Exploring the functionalities of RNA-binding protein 3 holds promise for uncovering new therapeutic approaches. Its critical role in adjusting protein synthesis rates and microRNA levels under different thermal conditions may provide insights into treating diseases linked to protein synthesis dysregulation.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.